Literature DB >> 1894354

Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

J L Arciniega1, R D Shahin, W N Burnette, T D Bartley, D W Whiteley, V L Mar, D L Burns.   

Abstract

An enzymatically deficient recombinant S1 subunit, in which Arg-9 was replaced by Lys, was combined with native B oligomer to form a mutant holotoxin molecule. This molecule exhibited decreased leukocytosis-promoting and histamine-sensitizing activities compared with those of the native toxin, supporting the view that the B oligomer is not responsible for these activities. The protective activity of this genetically attenuated pertussis toxin was compared with that of B oligomer alone. The mutant pertussis toxin and B oligomer were similarly capable of protecting mice against a respiratory infection with Bordetella pertussis, suggesting that the B oligomer makes a significant contribution to the protection afforded by the genetically attenuated holotoxin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894354      PMCID: PMC258899          DOI: 10.1128/iai.59.10.3407-3410.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.

Authors:  L Nencioni; M Pizza; M Bugnoli; T De Magistris; A Di Tommaso; F Giovannoni; R Manetti; I Marsili; G Matteucci; D Nucci
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

2.  Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.

Authors:  W N Burnette; W Cieplak; V L Mar; K T Kaljot; H Sato; J M Keith
Journal:  Science       Date:  1988-10-07       Impact factor: 47.728

3.  Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.

Authors:  A Kimura; K T Mountzouros; P A Schad; W Cieplak; J L Cowell
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Expression and immunological properties of the five subunits of pertussis toxin.

Authors:  A Nicosia; A Bartoloni; M Perugini; R Rappuoli
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

5.  Immune response to the B oligomer of pertussis toxin.

Authors:  J L Arciniega; D L Burns; E Garcia-Ortigoza; C R Manclark
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Structural characterization of pertussis toxin A subunit.

Authors:  D L Burns; S Z Hausman; W Lindner; F A Robey; C R Manclark
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

7.  Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination.

Authors:  M G Thomas; K Redhead; H P Lambert
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

8.  Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule.

Authors:  K Nogimori; M Tamura; M Yajima; K Ito; T Nakamura; N Kajikawa; Y Maruyama; M Ui
Journal:  Biochim Biophys Acta       Date:  1984-09-28

9.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.

Authors:  H Sato; A Ito; J Chiba; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice.

Authors:  M Oda; J L Cowell; D G Burstyn; C R Manclark
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

View more
  7 in total

1.  Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.

Authors:  S Z Hausman; D L Burns
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Identification of human T-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  J W Petersen; A Holm; P H Ibsen; K Hasløv; C Capiau; I Heron
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

5.  Identification of murine T-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  J W Petersen; A Holm; P H Ibsen; K Hasløv; I Heron
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 6.  Progress with a recombinant whooping cough vaccine: a review.

Authors:  W N Burnette; V L Mar; D W Whiteley; T D Bartley
Journal:  J R Soc Med       Date:  1992-05       Impact factor: 18.000

7.  Characterization of Individual Human Antibodies That Bind Pertussis Toxin Stimulated by Acellular Immunization.

Authors:  Edith Acquaye-Seedah; Elizabeth E Reczek; Hugh H Russell; Andrea M DiVenere; Sara O Sandman; Joseph H Collins; Caitlin A Stein; Timothy A Whitehead; Jennifer A Maynard
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.